The Clinical Study Of 10-Hydroxycamplothecin(HCPT) As Radiosensitivity Agent Plus Radiotherapy(RT) On Treatment Local Advanced Non-small Cell Lung Cancer (LANSCLC)

Concurrent combination of radiotherapy and chemotherapy is the primary model of treatment LANSCLC, it is difficuted to finish the period of treatment because of it's increased correlated side-effects .Based on previously clinical study, HCPT has broad spectrum in anti-carcinoma, and few correlated side-effect. Either single chemotherapy or combination chemotherapy , HCPT is an effective remedy on treatment LANSCLC. In vitro study showed that HCPT were more efficiancy in increasing sensitivity of radiotherapy. HCPT is an ideal radiosensitivity remedy in cocurrent combination radiotherapy and chemotherapy on treatment LANSCLC.The purpose of this study was to explore the maximum tolerated dose(MTD),dose-limited toxicity(DLT),proper phase II/III clinical dosage and observe the response and toxicity of HCPT as radiosensitivity in treatment of LANSCLC.Part One The Phase I Clinical Study on the HCPT as a Radiosensitivity Agent Plus RT on LANSCLC treatmentObjective: To investigate the maximum tolerated dose(MTD)and dose-limited toxicity(DLT)of HCPT as radiosensitivity in concurrent combination of RT in LANSCLC,Make sure the dose of HPCT in phase II/III clinical trial,to observe the clinical response in the near term, this study was conducted.Methods: Fifteen patients in stage III NSCLC were involved the study. All patients were treated by conventional fractionationed radiotherapy with a total tumor dose of 60Gy/30f/6w. HCPT treatment was began from the lowest...